In:
Cancer, Wiley, Vol. 127, No. 7 ( 2021-04), p. 1039-1048
Kurzfassung:
Blinatumomab and inotuzumab ozogamicin have comparable efficacy as a first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. The sequencing of these novel agents should be tailored according to individual patient needs.
Materialart:
Online-Ressource
ISSN:
0008-543X
,
1097-0142
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2021
ZDB Id:
1479932-7
ZDB Id:
2599218-1
ZDB Id:
2594979-2
ZDB Id:
1429-1